{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "shortName": "OVID THERAPEUTICS DL-,001", "messageBoardId": "finmb_288870432", "exchangeTimezoneShortName": "CEST", "market": "dr_market", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "longName": "Ovid Therapeutics Inc.", "regularMarketChangePercent": 0.0, "regularMarketPrice": 3.2, "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "regularMarketChange": 0.0, "regularMarketTime": 1683892036, "regularMarketDayHigh": 3.2, "regularMarketDayRange": "3.18 - 3.2", "regularMarketDayLow": 3.18, "regularMarketVolume": 850, "regularMarketPreviousClose": 3.2, "bid": 3.28, "ask": 3.34, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 3.18, "averageDailyVolume3Month": 14, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 1.7855, "fiftyTwoWeekLowChangePercent": 1.2622836, "fiftyTwoWeekRange": "1.4145 - 3.28", "fiftyTwoWeekHighChange": -0.07999992, "fiftyTwoWeekHighChangePercent": -0.02439022, "fiftyTwoWeekLow": 1.4145, "fiftyTwoWeekHigh": 3.28, "earningsTimestamp": 1683286200, "earningsTimestampStart": 1691409600, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.7, "epsForward": -0.83, "epsCurrentYear": 1.88, "priceEpsCurrentYear": 1.7021277, "sharesOutstanding": 70521296, "bookValue": 1.877, "fiftyDayAverage": 2.50333, "fiftyDayAverageChange": 0.69667006, "fiftyDayAverageChangePercent": 0.27829733, "twoHundredDayAverage": 2.044685, "twoHundredDayAverageChange": 1.1553152, "twoHundredDayAverageChangePercent": 0.5650334, "marketCap": 239743696, "forwardPE": -3.8554218, "priceToBook": 1.7048482, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.2 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1494828000000, "priceHint": 4, "symbol": "1OT.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "41 Ninth Avenue", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10001", "country": "United States", "phone": "646 661 7661", "fax": "646 661 4027", "website": "https://www.ovidrx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir", "age": 69, "title": "Pres, CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2022, "totalPay": {"raw": 923545, "fmt": "923.54k", "longFmt": "923,545"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey A. Rona", "age": 54, "title": "Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 686280, "fmt": "686.28k", "longFmt": "686,280"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jason  Tardio M.B.A.", "age": 45, "title": "Chief Operating Officer", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": {"raw": 652840, "fmt": "652.84k", "longFmt": "652,840"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D.", "age": 65, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1957, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lora  Pike", "title": "Sr. Director of Investor Relations & PR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas Michael Perone J.D., M.B.A.", "age": 57, "title": "Gen. Counsel, Chief Compliance Officer & Corp. Sec.", "yearBorn": 1965, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Simon D. Kelner", "age": 48, "title": "Chief HR Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Dirk  Haasner", "age": 57, "title": "Sr. VP of Global Manufacturing & CMC QA", "yearBorn": 1965, "fiscalYear": 2016, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR", "title": "Sr. VP of Culture & Facilities", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Claude  Nicaise M.D.", "age": 69, "title": "Head of R&D", "yearBorn": 1953, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}